Doug Drysdale is the Chief Executive Officer of Cybin. During Doug’s tenure as CEO of Cybin, the company was taken public on the NYSE and now has two clinical-stage programs in development for the treatment of major depressive disorder and generalized anxiety disorder, with its lead depression program in Phase 3 trials.